Delirium induced by clarithromycin in a patient with community-acquired pneumonia

Vicente de Vera C., Garcia M., Pifarre Teixido R., Barbe F.

Source: Eur Respir J 2006; 28: 671-672
Journal Issue: September
Disease area: Respiratory infections

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Vicente de Vera C., Garcia M., Pifarre Teixido R., Barbe F.. Delirium induced by clarithromycin in a patient with community-acquired pneumonia. Eur Respir J 2006; 28: 671-672

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010



Bacteraemia in outpatients with community-acquired pneumonia
Source: Eur Respir J 2016; 47: 654-657
Year: 2016


Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005

Efficacy of corticosteroids in hospital treated community-acquired pneumonia
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008


The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010


Treatment of nosocomial pneumonia with piperacillin-tazobactam
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007

Severe community-acquired pneumonia
Source: Eur Respir Monogr 2016; 74: 101-116
Year: 2016


Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020


Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 53s
Year: 2007

Corticosteroids and community-acquired pneumonia
Source: Annual Congress 2007 - Corticosteroids and respiratory failure
Year: 2007


Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression
Source: Eur Respir J 2012; 40: 1201-1210
Year: 2012



Mixed community-acquired pneumonia in hospitalised patients
Source: Eur Respir J 2006; 27: 795-800
Year: 2006



MRSA as a cause of community-acquired pneumonia
Source: Eur Respir J 2009; 34: 1013-1014
Year: 2009


Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009



The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008

Heliox-therapy of patients with execerbation of COPD and community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 106s
Year: 2006

Impact of aspiration pneumonia in community-acquired pneumonia and healthcare-associated pneumonia
Source: Annual Congress 2012 - CT findings: educational posters
Year: 2012